Cardiorentis Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Financing Rounds
  • 6

Cardiorentis General Information

Description

Developer of natriuretic peptide drugs committed to bringing novel therapies to the treatment of heart failure and related cardiovascular diseases. The company specializes in developing ularitide used for acute heart failure along with a safety and efficacy study of an intravenous placebo-controlled randomized infusion of ularitide in a prospective double-blind study in patients with symptomatic and decompensated chronic heart failures, ensuring its clients with improved outcome benefits for patients with cardiovascular disease and medicines for diseases of high unmet medical need.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly PE-Backed
Corporate Office
  • Steinhauserstrasse 74
  • 6300 Zug
  • Switzerland
+41 041
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • Steinhauserstrasse 74
  • 6300 Zug
  • Switzerland
+41 041

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cardiorentis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cardiorentis‘s full profile, request access.

Request a free trial

Cardiorentis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of natriuretic peptide drugs committed to bringing novel therapies to the treatment of heart failure and relat
Drug Discovery
Zug, Switzerland
9 As of 2016

Melbourne, Australia
 

Tokyo, Japan
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cardiorentis Competitors (13)

One of Cardiorentis’s 13 competitors is Mesoblast, a Corporation company based in Melbourne, Australia.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mesoblast Corporation Melbourne, Australia
SanBio Formerly VC-backed Tokyo, Japan
Orbsen Therapeutics Formerly PE-Backed Galway, Ireland
Vivus Corporate Backed or Acquired Campbell, CA
Cerenome Corporation Houston, TX
You’re viewing 5 of 13 competitors. Get the full list »

Cardiorentis Patents

Cardiorentis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2014208851-A1 A natriuretic peptide, a diuretic peptide or a vaso dilatory peptide for use in methods of treating cardiovascular indications Active 25-Jan-2013
AU-2014208851-B2 A natriuretic peptide, a diuretic peptide or a vaso dilatory peptide for use in methods of treating cardiovascular indications Inactive 25-Jan-2013
WO-2014115033-A3 A natriuretic peptide, a diuretic peptide or a vaso dilatory peptide for use in methods of treating cardiovascular indications Inactive 25-Jan-2013
EP-2948165-A2 A natriuretic peptide, a diuretic peptide or a vasodilatory peptide for use in methods of treating cardiovascular indications Inactive 25-Jan-2013
CA-2898571-A1 Methods of treating cardiovascular indications Inactive 25-Jan-2013 A61K38/2242
To view Cardiorentis’s complete patent history, request access »

Cardiorentis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cardiorentis Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cardiorentis‘s full profile, request access.

Request a free trial

Cardiorentis FAQs

  • When was Cardiorentis founded?

    Cardiorentis was founded in 2010.

  • Where is Cardiorentis headquartered?

    Cardiorentis is headquartered in Zug, Switzerland.

  • What is the size of Cardiorentis?

    Cardiorentis has 9 total employees.

  • What industry is Cardiorentis in?

    Cardiorentis’s primary industry is Drug Discovery.

  • Is Cardiorentis a private or public company?

    Cardiorentis is a Private company.

  • What is Cardiorentis’s current revenue?

    The current revenue for Cardiorentis is .

  • How much funding has Cardiorentis raised over time?

    Cardiorentis has raised $249M.

  • Who are Cardiorentis’s investors?

    has invested in Cardiorentis.

  • Who are Cardiorentis’s competitors?

    Mesoblast, SanBio, Orbsen Therapeutics, Vivus, and Cerenome are some of the 13 competitors of Cardiorentis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process